[Oral hypoglycemic drugs in chronic kidney disease: which limitations in the clinical setting]

MLA

Granata A, et al. [Oral Hypoglycemic Drugs in Chronic Kidney Disease: Which Limitations in the Clinical Setting]. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..7435d7cfadf213dd58afda7398613306&authtype=sso&custid=ns315887. Accessed 2 Dec. 2024.

APA

Granata A, Insalaco M, Pierpaolo Di Nicolò, Vr, S., Russo L, D’anna G, Lentini P, Fiorini F, & Fatuzzo P. (n.d.). [Oral hypoglycemic drugs in chronic kidney disease: which limitations in the clinical setting].

Chicago

Granata A, Insalaco M, Pierpaolo Di Nicolò, Scarfia Vr, Russo L, D’anna G, Lentini P, Fiorini F, and Fatuzzo P. 2024. “[Oral Hypoglycemic Drugs in Chronic Kidney Disease: Which Limitations in the Clinical Setting].” Accessed December 2. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..7435d7cfadf213dd58afda7398613306&authtype=sso&custid=ns315887.